Hallux is developing an investigational micro-insert for subungual delivery and treatment of distal lateral subungual onychomycosis. The dosage form is biodegradable and delivers high concentrations of terbinafine hydrochloride directly and selectively to the site of infection over a period of time. Results from pilot studies are encouraging and suggest that the subungual treatment procedure is safe and well tolerated. Hallux is planning to further evaluate efficacy, safety, and tolerability in a series of single site clinical studies commencing in the first half of 2016.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
12/17/15 | $7,100,000 | Series A |
Deerfield Management Company, L.P. | undisclosed |